Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Sponsor study identifier
observational
200
1 country
1
Study Start
October 2004
Actual (reported)Primary Completion
January 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2004
Actual (reported)September 12, 2005
Actual (reported)September 15, 2005
Actual (reported)January 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proteomics of Cutaneous T-cell lymphoma
Proteomic variables will be measured in blood and tissue of consented CTCL patients.
Ongoing
Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema may participate as appropriate with the potential for blood, tissue or urine sampling.
Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Subjects with cutaneous t-cell lymphoma and/or Sezary syndrome and atopic dermatitis or eczema patients
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
White blood cells and/or skin biopsy tissue are retained.
Oleg E Akilov, M.D., PhD
University of Pittsburgh
First Submitted
September 12, 2005
First Posted
September 15, 2005
Study Start
October 2004
Actual (reported)Primary Completion
January 2030
EstimatedDoxycycline for the Treatment of Cutaneous T-Cell Lymphoma
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
December 30, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: